MDT

96.1

-0.44%↓

A

137.81

-0.48%↓

VEEV

224.76

+0.38%↑

HQY

92.67

-0.47%↓

PHR.US

16.99

-0.18%↓

MDT

96.1

-0.44%↓

A

137.81

-0.48%↓

VEEV

224.76

+0.38%↑

HQY

92.67

-0.47%↓

PHR.US

16.99

-0.18%↓

MDT

96.1

-0.44%↓

A

137.81

-0.48%↓

VEEV

224.76

+0.38%↑

HQY

92.67

-0.47%↓

PHR.US

16.99

-0.18%↓

MDT

96.1

-0.44%↓

A

137.81

-0.48%↓

VEEV

224.76

+0.38%↑

HQY

92.67

-0.47%↓

PHR.US

16.99

-0.18%↓

MDT

96.1

-0.44%↓

A

137.81

-0.48%↓

VEEV

224.76

+0.38%↑

HQY

92.67

-0.47%↓

PHR.US

16.99

-0.18%↓

McKesson Corp

Затворен

СекторЗдравеопазване

829.45 0.23

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

823.34

Максимум

832.77

Ключови измерители

By Trading Economics

Приходи

426M

1.2B

Продажби

5.3B

103B

P/E

Средно за сектора

25.575

78.892

EPS

9.86

Дивидентна доходност

0.36

Марж на печалбата

1.173

Служители

43,000

EBITDA

212M

1.5B

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+13.75% upside

Дивиденти

By Dow Jones

Дивидентна доходност

Средно за сектора

0.36%

2.38%

Следващи печалби

4.02.2026 г.

Следваща дата на дивидент

2.01.2026 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-235M

102B

Предишно отваряне

829.22

Предишно затваряне

829.45

Настроения в новините

By Acuity

17%

83%

16 / 374 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Strong Bearish Evidence

McKesson Corp Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

29.12.2025 г., 22:03 ч. UTC

Значими двигатели на пазара

Mining Stocks Slip Near the End of Stellar Year

29.12.2025 г., 15:57 ч. UTC

Значими двигатели на пазара

Praxis Shares Rise on Ulixacaltamide Breakthrough Designation

29.12.2025 г., 23:43 ч. UTC

Пазарно говорене

Nikkei May Decline; Yen in Focus -- Market Talk

29.12.2025 г., 23:38 ч. UTC

Придобивния, сливания и поглъщания

Manus: Will Continue to Operate From Singapore

29.12.2025 г., 23:38 ч. UTC

Придобивния, сливания и поглъщания

Manus: Will Continue to Sell, Operate Product Subscription Service Through App, Website

29.12.2025 г., 23:37 ч. UTC

Придобивния, сливания и поглъщания

Meta Platforms: Will Integrate Manus Service Into Products

29.12.2025 г., 23:36 ч. UTC

Придобивния, сливания и поглъщания

Meta Platforms: Will Continue to Operate, Sell Manus Service

29.12.2025 г., 23:36 ч. UTC

Придобивния, сливания и поглъщания

Meta Platforms: Manus's Talent to Join Team to Deliver General-Purpose Agents Across Consumer, Business Products

29.12.2025 г., 23:35 ч. UTC

Придобивния, сливания и поглъщания

Manus to Join Meta Platforms

29.12.2025 г., 21:33 ч. UTC

Придобивния, сливания и поглъщания

Origin: Raise Values Kraken at US$8.65 Billion

29.12.2025 г., 21:33 ч. UTC

Придобивния, сливания и поглъщания

Origin: Octopus Targeting Kraken Separation by Mid 2026

29.12.2025 г., 21:31 ч. UTC

Придобивния, сливания и поглъщания

BlueScope: Rezoning Will Allow for Range of Commercial, Industrial Development Uses

29.12.2025 г., 21:31 ч. UTC

Придобивния, сливания и поглъщания

BlueScope Also Says Land Adjacent to Port Kembla Steelworks Rezoned to Special Purpose

29.12.2025 г., 21:30 ч. UTC

Придобивния, сливания и поглъщания

Origin's Kraken Stake to Remain at 22.7%

29.12.2025 г., 21:30 ч. UTC

Придобивния, сливания и поглъщания

Origin Will Continue to Hold Its 22.7% Interest in Octopus

29.12.2025 г., 21:30 ч. UTC

Придобивния, сливания и поглъщания

BlueScope: Guidance Reflects Sustained Strength of Operating Performance in Recent Months

29.12.2025 г., 21:30 ч. UTC

Придобивния, сливания и поглъщания

Origin: Additional Interest Offsets Dilution From Raise

29.12.2025 г., 21:30 ч. UTC

Придобивния, сливания и поглъщания

BlueScope Doesn't Expect Material Impact on 1H Guidance Range

29.12.2025 г., 21:29 ч. UTC

Придобивния, сливания и поглъщания

Origin Waiving Australia Exclusivity to Kraken in Exchange for Additional 1.5% Equity Interest

29.12.2025 г., 21:29 ч. UTC

Придобивния, сливания и поглъщания

BlueScope Expects to Complete Property Sale for A$76 Million Consideration

29.12.2025 г., 21:29 ч. UTC

Придобивния, сливания и поглъщания

BlueScope Expects to Complete Property Sale in 2H of FY 2026

29.12.2025 г., 21:28 ч. UTC

Придобивния, сливания и поглъщания

BlueScope: Selling Residentially Zoned Land in West Dapto to Large Homebuilder

29.12.2025 г., 21:28 ч. UTC

Придобивния, сливания и поглъщания

Origin: Kraken's Raise Paves Way for Separation From Octopus Energy

29.12.2025 г., 21:28 ч. UTC

Придобивния, сливания и поглъщания

Origin: Kraken to Raise Total US$1 Billion From New, Existing Investors

29.12.2025 г., 21:28 ч. UTC

Придобивния, сливания и поглъщания

BlueScope Steel Exchanges Contracts for Sale of 33 Hectares of Land in West Dapto

29.12.2025 г., 21:27 ч. UTC

Придобивния, сливания и поглъщания

Origin Energy to Invest US$140M in Kraken's Standalone Equity Raise

29.12.2025 г., 20:22 ч. UTC

Пазарно говорене

Oil Rebounds As Russia-Ukraine War Seen Continuing -- Market Talk

29.12.2025 г., 20:14 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Rise As Front Month Expires -- Market Talk

29.12.2025 г., 20:02 ч. UTC

Придобивния, сливания и поглъщания

Union Pacific--Norfolk Southern Merger Targets Trucking Market Share -- Barrons.com

29.12.2025 г., 17:36 ч. UTC

Пазарно говорене

U.S. Natural Gas Inventories Swing to Deficit Vs. 5-Year Average -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

McKesson Corp Прогноза

Ценова цел

By TipRanks

13.75% нагоре

12-месечна прогноза

Среден 942.18 USD  13.75%

Висок 1,000 USD

Нисък 880 USD

Според 14 анализатори от Wall Street, предложили 12-месечна ценова цел за McKesson Corp през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

14 ratings

12

Купи

2

Задържане

0

Продай

Техническа оценка

By Trading Central

681.92 / 707.28Подкрепа & съпротива

Краткосрочен план

Strong Bearish Evidence

Средносрочен план

No Evidence

Дългосрочен план

No Evidence

Настроение

By Acuity

16 / 374 Класиране в Здравеопазване

Настроения в новините

Много силни бичи доказателства

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно McKesson Corp

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products. This segment also offers practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices; and consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies. The RxTS segment serves biopharma and life sciences partners, and patients to address medication challenges for patients by working across healthcare; connects patients, pharmacies, providers, pharmacy benefit managers, health plans, and biopharma companies to deliver innovative solutions to help people get the medicine needed to live healthier lives; and provides prescription price transparency, benefit insight, dispensing support, third-party logistics, and wholesale distribution support services. The Medical-Surgical Solutions segment offers medical-surgical supply distribution, logistics, and other services to healthcare providers, including physician offices, surgery centers, nursing homes, hospital reference labs, and home health care agencies. The International segment provides distribution and services to wholesale, institutional, and retail customers in Europe and Canada. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.
help-icon Live chat